Expired activity
Please go to the PowerPak homepage and select a course.

The Expanding Role of the Pharmacist in HIV Prevention:
What Do You Know About PrEP?

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
PIM  Integritas Communications

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

For questions regarding the accreditation of this program, please contact Postgraduate Institute for Medicine (PIM) at www.pimed.com

Release date

March 5, 2018

Expiration date

March 5, 2019

Estimated time to complete activity

1.0 hour

Target Audience

This activity is intended for pharmacists engaged in the care of patients at risk for HIV.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Provide proactive, universal HIV-risk screening, identify patients at substantial risk for HIV acquisition, and determine PrEP eligibility
  • Create open patient-provider dialogue and engage the patient as an active, educated participant in clinical decision-making, ongoing patient-centric monitoring, and comprehensive risk-reduction strategies
  • Counsel patients regarding PrEP efficacy, safety, and optimal use, and offer treatment-adherence counseling to patients receiving PrEP
  • Provide ongoing guideline-based clinical and laboratory monitoring for patients receiving PrEP

Statement of Need / Program Description

The most recent estimates from the Centers for Disease Control and Prevention (CDC) state that approximately 37,000 people in the United States become infected with HIV each year.1 To reduce the number of new infections, health care providers should be prepared to discuss the potential benefits of preexposure prophylaxis (PrEP) with adults who are at particularly high risk for acquiring HIV.2 The United States Public Health Service (USPHS) and the CDC have published clinical practice guidelines on identifying candidates and prescribing medication approved by the US Food and Drug Administration (FDA) for HIV PrEP.3 During this Interactive Exchange™ program, expert faculty will review these guidelines with a focus on how pharmacists can facilitate patient engagement and retention in HIV-prevention services.4 Key topics will include recommendations on universal HIV testing, cohorts at substantial risk for HIV acquisition, criteria for PrEP eligibility, and practical approaches to monitoring PrEP outcomes and adherence.1 Faculty will also discuss the growing evidence pool supporting pharmacy-based programs to highlight opportunities for program attendees to play increasingly central roles in the prevention of new HIV infections.5

  1. CDC. CDC fact sheet: HIV incidence: estimated annual infections in the U.S., 2008-2014. Overall and by transmission route. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-incidence-fact-sheet_508.pdf. Updated February 2017. Accessed October 31, 2017.
  2. Truvada (emtricitabine/tenofovir disoproxil fumarate) [prescribing information]. Initial US approval 2004. Foster City, CA: Gilead Sciences, Inc; 2017.
  3. CDC. USPHS Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2014. https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed October 31, 2017.
  4. CDC. Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html. Updated March 2017. Accessed October 31, 2017.
  5. CDC. Innovative CDC effort expands HIV testing into pharmacies. http://www.cdc.gov/nchhstp/newsroom/2012/nhtdpressrelease2012.html. Published June 2012. Accessed October 31, 2017.


Richard A. ElionRichard A. Elion, MD (Virtual Professor)
Associate Clinical Professor of Medicine
George Washington University School of Medicine
Director, Clinical Research
Whitman-Walker Health
Washington, DC

scott jamesJames D. Scott, BS, MEd, PharmD
Associate Dean
Experiential and Professional Affairs
Professor, Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, California

Elyse TungElyse Tung, PharmD, BCACP
Clinical Assistant Professor
University of Washington School of Pharmacy
Director of Clinical Services
Kelley-Ross Pharmacy at the Polyclinic
Seattle, Washington

Joint Accreditation Statement

Jointly Accredited ProviderIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

acpePostgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-18-307-H02-P)

Type of Activity


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Richard A. Elion, MD
Consulting fees: Gilead Sciences, Inc.; ViiV Healthcare
Fees for non-CME/CE services: Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.
Contracted research: Gilead Sciences, Inc.

James D. Scott, BS, MEd, PharmD
Has nothing to disclose.

Elyse Tung, PharmD, BCACP
Honoraria: Gilead Sciences, Inc.
Fees for non-CME/CE services: Gilead Sciences, Inc.

Planners and Managers

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The Integritas Communications planners and managers, Jim Kappler, PhD, and Jeanette Ruby, MD have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving credit for this activity. During the period March 5, 2018 through March 5, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.



Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.